NCT06922110Enrolling By Invitation3 期
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- Enrolling By Invitation
- 入组人数
- 460
- 试验地点
- 86
- 主要终点
- Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest
研究概览
简要总结
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant successfully completed the treatment period of an antecedent azetukalner Phase 3 study in MDD.
- •Participant provides written informed consent to participate in the study, is able to understand the procedures and study requirements, and agrees to abide by them.
- •Participant is willing to comply with the contraception requirements.
- •Male participants must agree not to donate sperm until 3 months after the last dose of study drug. Female participants must agree not to donate ova until 3 months after the last dose of study drug.
排除标准
- •Participant met any of the withdrawal criteria, or discontinued study drug early, or was terminated early from an antecedent study.
- •Participant had any protocol deviations in an antecedent azetukalner study that, in the opinion of the investigator, would preclude participation in this study.
- •Participant is unable to comply with study procedures or is inappropriate for the study, as judged by the investigator.
- •Participant has any medical condition, personal circumstance, or ongoing AE (from an antecedent study) that, in the opinion of the investigator, exposes the participant to unacceptable risk by participating in the study or prevents adherence to the protocol.
- •Female participant who is pregnant, breastfeeding, or planning to become pregnant within 3 months after the last dose of study drug.
- •Participant is planning to enter a clinical study with a different investigational drug or planning to use any experimental device for treatment of any medical condition during the study or within 28 days after completion of this study.
- •Participant is judged to have a significant risk for self-harm or suicidal behavior or is considered to be an imminent danger to themself or others, as determined by the C-SSRS or in the opinion of the investigator.
研究组 & 干预措施
Azetukalner 20 mg
Experimental
干预措施: Azetukalner (Drug)
结局指标
主要结局
Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest
时间窗: From the start of treatment in the open-label extension study through 8 weeks after the last dose
次要结局
- Change from baseline in the Hamilton Depression Rating Scale, 17-Item (HAMD-17) total score over time(From baseline through the active extension treatment (Week 52))
- Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time(From baseline through the active extension treatment (Week 52))
- Change in the Clinical Global Impression of Severity (CGI-S) score over time(From baseline through the active extension treatment (Week 52))
- Change from baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) total score, Q-LES-Q-SF medication and life satisfaction and contentment in item scores over time(From baseline through the active extension treatment (Week 52))
- Change from baseline in Sheehan Disability Scale (SDS) total score and subscale scores over time(From baseline through the active extension treatment (Week 52))
研究者
研究点 (86)
Loading locations...
相似试验
已完成
3 期
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresEpilepsyNCT01777139GlaxoSmithKline30
招募中
2 期
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT06745622Haisco Pharmaceutical Group Co., Ltd.47
已完成
3 期
Long Term Safety Study of PlecanatideIrritable Bowel SyndromeNCT02706483Bausch Health Americas, Inc.2,272
已完成
3 期
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal PeriodPrader-Willi SyndromeNCT03714373Soleno Therapeutics, Inc.115
已完成
3 期
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaHyperlipidemia and Mixed DyslipidemiaNCT01854918Amgen3,681